Study analysis shows outcomes for infants with HIV who started antiretroviral therapy very early in life.

Tuesday, December 5, 2023 Outcomes of Very Early Treatment for Infants Who Acquired HIV In Utero Colorized transmission electron micrograph of HIV-1 virus particles (red) budding and replicating from an H9 T cell (blue). The virus particles are in various stages of maturity, which accounts for differences in shape. Captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID Long-term data from a study implemented by the NIH-funded International Maternal Pediatric Adolescent AIDS Clinical Trials network showed very early antiretroviral therapy (ART) for infants who acquired HIV in utero enabled some infants to sustain viral suppression for more than two years. Of children whose HIV remained suppressed, a majority continued to show no evidence of the latent HIV reservoirs that contribute to lifelong persistent infection. The next phase of the study involves a planned interruption in ART for children meeting prespecified criteria to observe whether they remain free of HIV, while closely monitoring their overall health. The latest study findings are published in The Lancet HIV. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107